A recent study reveals that STC1 is a novel biomarker associated with immune characteristics and prognosis of bladder cancer [38] and also inhibits APC phagocytosis, contributes to tumor immune evasion and immunotherapy resistance [39]. Here, STC1 is linked to urinary bladder carcinoma.